vendredi 14 février 2020

Onco Actu du 14 février 2020

Pour information, Onco Actu interrompt sa parution pendant une semaine. 
Prochain numéro : lundi 24 février


1. BIOLOGIE




Childhood Brain Tumor Discovery May Unlock New Treatments for Many Cancers [University of Virginia]











2. ETIOLOGIE




Weight-loss drug to be pulled from market after FDA expresses concerns on cancer risk [STAT]











8 years after its OK, Eisai yanks its flailing obesity drug from the market after FDA flagged higher cancer rate [EndPoints]












FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market [FDA]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC




Researchers describe recently discovered condition involving numerous gastrointestinal polyps in childhood cancer survivors [Dana-Farber Cancer Institute]











4.2 DÉP., DIAG. & PRONO. - GÉNOME




There could soon be a test to detect cancer years in advance. Would you take it? [The Guardian]











5.1 TRAITEMENTS - PRÉ-CLINIQUE




Scientists stop breast cancer cells from spreading in the lab [University of Manchester]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES




Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date [Fierce Biotech]











Bristol-Myers finds FDA receptive to speedy review of key cell therapy [Biopharma Dive]












U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma [BMS]












Bristol-Myers checks off another milestone on the Celgene CVR, hustling Yescarta rival to the market [EndPoints]











5.12.5 IMMUNOTHÉRAPIES - PHARMA




China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer [Roche]












Roche scores its first PD-L1 win in China, going straight for SCLC niche [EndPoints]











5.17 TRAITEMENTS - RADIOTHÉRAPIE




Much shorter radiation treatment found to be safe, effective for people with soft tissue sarcoma [UCLA]











5.2 PHARMA




Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer [Seattle Genetics]












Seattle Genetics gets another drug close to the finish line [EndPoints]











5.2.3 PHARMA - ÉCONOMIE




How will coronavirus hit U.S. drugmakers? Depends what kind of drugmaker you are: Moody's [Fierce Pharma]











5.2.6 PHARMA - BIOTECH




What Happens to University-Based Biotech Startups – And Why [In The Pipeline]










5.2.6.1 PHARMA - BIOTECH - REVOLUTION




Revolution pulls off $238M IPO to push KRAS pipeline into the clinic [Fierce Biotech]












The cancer genes Wall Street is flooding with cash [Biopharma Dive]











The RAS rush: Revolution Medicines bags remarkable $238M IPO raise, more than doubling original goal [EndPoints]











5.2.6.2 PHARMA - BIOTECH - DECIPHERA




Deciphera nabs speedy review for GIST cancer hopeful [Fierce Biotech]












Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors [Deciphera]












Deciphera's GIST therapy ripretinib wins speedy FDA review — setting the stage for battle with rival Blueprint [EndPoints]











5.5.19 ASCO (REIN)




Targeted drug shows promise in advanced kidney cancer [Harvard Gazette]











5.5.3 ASCO (PROSTATE)




Bayer to highlight data from its expanding cancer portfolio at 2020 ASCO GU Cancers Symposium [Bayer]











6.1 OBSERVATION




Saying sex increases cancer risk is neither totally correct, nor in any way helpful [The Conversation]











Skin cancer "more common" among gay and bisexual men [NHS Choices]











Link Between Genetic Variant and Poor Outcomes in Men with Advanced Prostate Cancer Validated [Cleveland Clinic]











6.10.1 POLITIQUES (USA)




Funding the Global Benefits to Biopharmaceutical Innovation [White House]












The White House review of drug prices: Don't hate the player — hate the game [EndPoints]